Bristol-Myers Squibb Opdivo and Yervoy are approved in the UK for the treatment of malignant pleural mesothelioma

A few days ago, the British Medicines and Health Products Regulatory Agency (MHRA) approved Bristol-Myers Squibb's (BMS) blockbuster Opdivo (nivolumab) and Yervoy (ipilimumab) immunocombination therapy for the first-line treatment of unresectable malignant pleural mesothelioma (MPM).

The successful supervision also means that Opdivo and Yervoy immunotherapy have the opportunity to expand the market for new indications

The results of the trial showed that through the shortest 22.

In the trial, the safety of the Opdivo and Yervoy immunotherapy combination therapy was consistent with the results of previously reported studies, and no new safety signals were observed

Opdivo and Yervoy immune combination therapy is a combination of two immune checkpoint inhibitors.

In addition to malignant pleural mesothelioma, Opdivo and Yervoy immunotherapy have recently achieved regulatory breakthroughs in other indications

Reference source: MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma